-+ 0.00%
-+ 0.00%
-+ 0.00%
On November 17, Cinda Biopharmaceuticals Group announced that Takeda Pharmaceuticals has been granted Tankan atotamab SAKIGAKE certification by the Ministry of Health, Labor, and Welfare of Japan. The proposed indication is CLDN 18.2 positive, unresectable, advanced or recurrent gastric or gastroesophageal junction adenocarcinoma (G/GEJA) that progresses after chemotherapy.
Share
Listen to the news
On November 17, Cinda Biopharmaceuticals Group announced that Takeda Pharmaceuticals has been granted Tankan atotamab SAKIGAKE certification by the Ministry of Health, Labor, and Welfare of Japan. The proposed indication is CLDN 18.2 positive, unresectable, advanced or recurrent gastric or gastroesophageal junction adenocarcinoma (G/GEJA) that progresses after chemotherapy.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending